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ABSTRACT
Objectives: Adherence to nebulised treatment is typically low
among people with cystic fibrosis (CF). This study sought to
identify factors differentiating high or low nebuliser adherence
patterns (i.e. ≥80% or <50% of all nebulised treatments over one
year) among adults with CF.
Design: A mixed methods cross-sectional exploratory comparison
of low and high adherers to nebulised medications.
Methods: Of 36 eligible adults invited from a UK CF centre, 20 were
recruited (10 high, 10 low adherers). Adherence was objectively
measured using electronic data capture. Participants completed a
self-report questionnaire comprising measures of hypothesised
predictors (habit, self-control, life chaos, perceived treatment
burden, capability, motivation and opportunity), then took part in
a semi-structured interview. Quantitative data were compared
between groups, and interview data were thematically analysed.
Results: High adherers reported stronger habit and greater
opportunities, though habit and perceived opportunity scores
were highly positively correlated. No other quantitative measure
distinguished between groups. Habitual instigation tendency
attenuated the relationship between treatment complexity and
perceived treatment burden. Indeed, in interviews, high adherers
reported that routinisation and greater automaticity made
treatment burden more manageable.
Conclusions: High adherers seized more opportunities for nebuliser
use, adapted their lives more effectively to using nebulisers and
were more likely to make nebuliser use habitual. Nebuliser
adherence interventions among adults with CF might usefully
target development of routines for instigating nebuliser use, and
identification of opportune moments for nebuliser use.
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Introduction
Cystic fibrosis (CF), which affects around 10,000 people in the UK, is a genetic condition
which causes the lungs and digestive system to become clogged with thick mucus (UK
Cystic Fibrosis Trust, 2016). This leads to many challenging symptoms, including recur-
rent lung infections and reduced nutrient absorption from food (O’Sullivan & Freedman,
2009). Median survival is around 45–50 years (Burgel et al., 2015). Over 80% of mortality
is due to progressive lung function decline and respiratory failure (O’Sullivan & Freedman,
2009).
Inhaled treatments are vital to prevent acute deterioration in lung health (i.e. pulmon-
ary exacerbations) and so reduce the rate of lung function decline (Agent & Parrott, 2015).
These treatments are usually delivered via a nebuliser, and typically consist of once or
twice-daily mucolytics to augment airway clearance and twice-daily antibiotics to eradi-
cate infection or to prevent pulmonary exacerbations. High adherence is associated
with reduced lung function decline, fewer pulmonary exacerbations and lower treatment
costs (Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 2011; Quittner et al., 2014).
However, in the US and UK, adherence is only around 30–50% (Daniels et al., 2011; Quitt-
ner et al., 2014). At present, there are no effective nebuliser adherence interventions for
people with CF (Glasscoe & Quittner, 2008; Savage et al., 2011).
Improving adherence requires understanding the determinants of adherence to inhaled
treatments among people with CF. There is, however, scant research in this area.
Qualitative studies in CF have tended to identify ‘treatment burden’ – that is, the dur-
ation, frequency and complexity of treatment regimes – and competing work or social
demands as most problematic for nebuliser use (George et al., 2010; Hogan, Bonney,
Brien, Karamy, & Aslani, 2015; Sawicki, Heller, Demars, & Robinson, 2015). People
with CF typically spend 2–3 hours daily preparing and using treatments, with airway
clearance and inhaled treatments particularly time-consuming (Hafen, Kernen, & De
Halleux, 2013; Sawicki, Sellers, & Robinson, 2009). Similarly, quantitative studies have
suggested that ‘lack of time’, ‘forgetting’ and ‘being too busy’ are significant barriers to
nebuliser use, especially among adolescents (Bregnballe, Schiøtz, Boisen, Pressler, &
Thastum, 2011; Dziuban, Saab-Abazeed, Chaudhry, Streetman, & Nasr, 2010). Yet, objec-
tive adherence data, collected using the I-neb® adaptive aerosol delivery nebuliser system,
which accurately logs every nebuliser use episode (Geller & Madge, 2011), have demon-
strated that adolescents with CF are most adherent during school term-time weekdays
(Ball et al., 2013). This is when adolescents are likely to be busiest, and so most susceptible
to lapse due to treatment burden. Furthermore, alternative treatments developed to alle-
viate burden – such as dry powder inhalers, which are quicker to inhale and do not require
cleaning – have produced only short-term improvements in self-reported adherence
(Brown et al., 2015; Harrison et al., 2014). Treatment burden may not therefore offer a
sufficient explanation for low adherence.
Most studies of adherence determinants among people with CF have eschewed explicit
psychological theory (but see Hogan et al., 2015). Yet pertinent medication adherence the-
ories are available. For example, the Necessity-Concerns Framework posits that patients
adhere where perceived necessity exceeds concerns around medication (Horne et al.,
2013). Indeed, across various long-term conditions, ‘necessity’ beliefs correlate positively
and ‘concern’ beliefs negatively with medication adherence (Foot, La Caze, Gujral,
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& Cottrell, 2016; Horne et al., 2013). The Perceptions and Practicalities Approach (PAPA)
proposes that non-adherence can be intentional, arising from attitudinal barriers (e.g. lack
of necessity, overwhelming concerns), or unintentional, arising from practical barriers
(e.g. lack of time). Intentional non-adherence has been cited as a major treatment
barrier in CF (George et al., 2010; Hogan et al., 2015; Sawicki et al., 2015).
Both empirical studies of nebuliser use barriers among people with CF, and dominant
broader theories of medication adherence, have assumed that adherence arises from
rational deliberation. Yet, dual process theories propose that behaviour may be directed
either via conscious deliberation, or through more rapid, automatic processing (e.g.
Strack & Deutsch, 2004). The Capability, Opportunity and Motivation (COM-B)
model, which incorporates all potential determinants of action (Michie, van Stralen, &
West, 2011), posits three factors necessary for any behaviour to occur: perceptions of capa-
bility, opportunity and motivation. Each of these may be subdivided: capability may be
psychological (e.g. knowledge) or physical (e.g. dexterity); opportunity may be social
(e.g. permission to use nebulisers at the workplace) or physical (e.g. medication avail-
ability) and, in light of dual process models, motivation may be reflective and deliberative
(e.g. necessity, concerns) or non-reflective, drawing on automatic processes (e.g. habit
associations). Factors such as intentional non-adherence represent inaction arising from
a lack of reflective motivation for nebuliser use.
The COM-B model demands explanations for low adherence over and above treatment
beliefs, which are one component of reflective motivation. In addition, understanding
nebuliser adherence requires focusing not only on those with low adherence, but those
who consistently adhere. Some people can maintain consistently high adherence for
many years (McNamara, McCormack, McDonald, Heaf, & Southern, 2009). ‘High
adherers’ may have better self-regulatory skills or resources (i.e. greater psychological
capability). Self-regulation is effortful and uses up limited mental resources (Baumeister
& Alquist, 2009). Previous studies have identified adults with CF intentionally not
using nebuliser, to better cope with other concurrent treatments (Hogan et al., 2015).
Others have found alternating regimes of inhaled tobramycin (28 days on treatment fol-
lowed by 28 days off) to be more tolerable than continuous regimes of inhaled mucolytics
(Dziuban et al., 2010), which may reflect a need to replenish self-regulatory capacity
during non-use periods (Baumeister & Alquist, 2009).
High adherers may perhaps also be better able to routinise nebuliser use. ‘Routinisation’
– that is, the fostering of contextually stable and persistent behavioural patterns – has been
shown to facilitate nebuliser use (George et al., 2010; Hogan et al., 2015). This raises the
possibility that long-term nebuliser use may be sustained by non-reflective motivational
processes. One such process is ‘habit’, by which situational cues (e.g. time) automatically
activate impulses towards action (i.e. nebuliser use), based on learned cue-behaviour
associations (Gardner, 2015). Habits form through a process of ‘context-dependent rep-
etition’, whereby repeated performance in the consistent presence of environmental
cues (e.g. location or mood) reinforce the mental cue-action association, such that
merely encountering cues is sufficient to prompt an unconscious impulse to act
(Gardner, 2015). Habit formation is thought to support frequent repetition with
minimal cognitive effort, and may dominate over conscious intentions, shielding behav-
iour against possible lapses in reflective motivation (Gardner, de Bruijn, & Lally, 2011;
Rothman, Sheeran, & Wood, 2009). Unstable contexts may thus preclude habit formation
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(Lally & Gardner, 2013). ‘Chaotic’ lifestyles, which lack structure and predictability
(Wong, Sarkisian, Davis, Kinsler, & Cunningham, 2007), are associated with lower medi-
cation adherence (Wong et al., 2007; Zullig et al., 2013).
Habitual actions can be discerned into two types: habitually instigated sequences
(action sequence automatically initiated without deliberation) and habitually executed
actions (action performed to completion without conscious input; Gardner, 2015;
Gardner, Phillips, & Judah, 2016; Phillips & Gardner, 2016). Habitual instigation does
not necessitate habitual execution, and vice versa; a nebuliser use episode may be habitu-
ally instigated but the nebuliser used non-habitually (e.g. triggered at the same time of day,
but performed mindfully in a varying sequence) or the episode non-habitually instigated
but habitually performed (e.g. mindfully triggered, but performed in an automated and
unvarying sequence; Gardner, 2015). While habitual instigation tendency is likely to
predict the frequency of nebuliser use episodes (Gardner et al., 2016; Phillips &
Gardner, 2016), habitual execution tendencies may perhaps also support adherence, by
making progression through the procedural intricacies of nebuliser use easier to
perform (Gardner et al., 2016).
The present study
Previous studies of the determinants of nebuliser adherence among people with CF have
focussed on self-reported adherence, reflective motivational constructs and barriers
among low adherers, rather than facilitators among high adherers. Theory suggests that
both reflective and non-reflective processes influence medication adherence among
adults with CF, but this has yet to be empirically explored. The present study therefore
used objective adherence data to identify both low and high adherers, and explored reflec-
tive and non-reflective processes that may discriminate between these two groups. This
exploratory study, designed to generate ideas for testing in a larger sample, could point
to potentially valuable avenues of future research A mixed methods design was used
(Curry et al., 2013) with quantitative analyses of relationships between potential determi-
nants and adherence, and a realist qualitative analysis to offer in-depth insights into the
specific beliefs, attitudes and values that may underpin such relationships.
Method
Procedure
This was a mixed methods cross-sectional exploratory study among adults with CF,
selected to represent high nebuliser adherence (≥80% annual adherence), and low nebu-
liser adherence (<50% annual adherence). Adherence of≥80% is considered ‘high’ because
such an adherence rate yields better health outcomes (Eakin et al., 2011; Karve et al., 2009).
Adherence of <50% indicates a general tendency not to adhere, and is considered ‘low’
(Eakin et al., 2011).
People with CF aged ≥16 years were identified by their clinical team and sent a study
information pack two weeks before their routine clinical visits. Data collection was timed
to coincide with routine review visits. After review by their usual clinical team, which in
accordance with standard procedures involved provision of personalised feedback on
objective nebuliser adherence level, a researcher (HZH) approached potential participants
302 Z. H. HOO ET AL.
and invited them to take part. Details of all prescribed treatments were collected from
those who consented and checked against medical records. Next, participants completed
a questionnaire comprising measures of potential adherence predictors, and subsequently
a face-to-face semi-structured interview. Interviews lasted 30–60 minutes to broadly
explore patients’ experiences around nebuliser use. The interview topic guide was suffi-
ciently open to allow emergence of new insights (see Appendix). The topic guide was
informed by the extant literature in similar clinical areas (e.g. Hogan et al., 2015), and
the clinical experience and expertise of the research team. It was refined after the first
four interviews, taking into account the results of those initial interviews. Digitally
recorded interviews were transcribed verbatim. Participants were offered the option to
review their own interview transcript for data verification. All the participants were
known to HZH who performed the interviews and analysed the data, since he worked
as a doctor with the CF clinical team for ∼18 months prior to data collection. However,
nebuliser adherence is not an issue that typically entails detailed discussion between
doctors and adults with CF in the centre, with physiotherapists taking a lead on this for
the multidisciplinary team. Approval for the study was granted by a National Research
Ethics Service Committee.
Participants
Participants were recruited from an adult CF Centre in the North of England, which at the
time of data collection (May–August ‘15) had ∼200 registered patients aged≥ 16 years
diagnosed, to UK CF Trust criteria, as having CF. Eligible participants with CF used
I-neb® as part of their treatment and had baseline objective annual adherence of either
≥80% or <50%. People in the palliative phase of disease, pregnant women, those with
transplanted lungs or actively listed for lung transplantation, or lacking capacity to
consent were excluded.
We set a target sample size of 20–24 patients (i.e. 10–12 people with ≥80% adherence,
10–12 with <50% adherence). This was deemed sufficient to achieve theoretical saturation
in qualitative analysis (Guest, Bunce, & Johnson, 2006; Onwuegbuzie & Leech, 2007),
while also feasible given a limited pool of eligible participants within a single CF centre.
Of 36 eligible adults with CF (18 high, 18 low adherence) attending clinical reviews in
May–August 2015, 20 participated (10 high, 10 low adherence; 56% recruitment rate).
Measures
Health outcomes
Health data were obtained from medical notes. Best lung function was operationalised as
the highest % predicted forced expiratory volume in 1 second (FEV1) calculated with the
Knudson equation (Knudson, Lebowitz, Holberg, & Burrows, 1983) for a 1-year period up
to the day of recruitment. Pulmonary exacerbations severity and frequency were captured
via total intravenous (IV) antibiotic days over the same 1-year period.
Nebuliser adherence
Adherence was calculated using objective data downloaded from I-neb® as ‘unadjusted
adherence’, that is, as a percentage between total amount of medication used against
the agreed dose between clinicians and adults with CF (Hoo et al., 2016).
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Hypothesised predictors of adherence
These were chosen based on a review of previous literature (see Introduction, paragraphs
7–9). Unless stated, all hypothesised predictors were self-reported using statements with
which participants rated agreement from 1 (strongly disagree) to 7 (strongly agree).
These statements are listed in the Appendix.
Treatment burden was measured in two ways. ‘Objective’ burden was measured via the
Treatment Complexity Score (Sawicki et al., 2013), which assigns a value of 1, 2 or 3 (3 =
highest burden) to the 37 CF maintenance therapies, producing a single score from 0 (no
burden) to 72 (highest burden). ‘Subjective’ burden was self-reported using two statements
modified from the CF Questionnaire-Revised (CFQ-R; Quittner, Buu, Messer, Modi, &
Watrous, 2005; e.g. ‘My nebuliser treatment makes my daily life more difficult’; α
= .74). These two statements were chosen from the three statements in CFQ-R that
measure treatment burden, since they have the best face validity.
Self-regulation was measured with all eight statements from the Brief Self-Control Scale
(Tangney, Baumeister, & Boone, 2004; e.g. ‘I am good at resisting temptation’; α = .68).
Life chaos was measured via all six statements from the Modified Confusion, Hubbub
and Order Scale Life (Wong et al., 2007; e.g. ‘My life is organised’; α = .68).
Habit was measured in three ways. The habitual nature of nebuliser use was measured
using all four statements from the Self-Report Behavioural Automaticity Index (SRBAI;
Gardner, Abraham, Lally, & de Bruijn, 2012), a validated subscale of the Self-Report
Habit Index (Verplanken & Orbell, 2003). A sequence of ‘habitual’ behaviour can be
habitually triggered (habitual instigation) and/or automatically performed to completion
after being triggered (habitual execution; Gardner et al., 2016). As originally formulated
however, the SRBAI does not distinguish between habitual instigation or execution, but
rather offers a non-specific habit measure that potentially incorporates elements of insti-
gation and execution (Gardner et al., 2016). The original SRBAI wording formulation was
used to measure non-specific habit with four items (e.g. ‘Using my nebuliser is something I
do automatically’; α = .82). To aid identification of the precise location of habit in nebuliser
use sequences, habitual instigation and habitual execution were also measured. To mini-
mise participant burden, habitual instigation and execution were each measured using a
single item from the SRBAI, which differed only in the item stem (instigation: ‘Deciding
to use my nebuliser… ’; execution: ‘Once I have decided to use my nebuliser, using my
nebuliser … ’ [‘ … is something I do without having to consciously remember’];
Gardner et al., 2016). This item was selected on the basis that, of four SRBAI items, it
showed the strongest item-total agreement in pilot data among 15 adults with CF
(Curley, 2014).
Intention (e.g. ‘I intend to use my nebuliser’; α = .88), opportunity (α = .38) and capa-
bility (α = –.43) were each measured using two statements with the best face validity to
represent nebuliser use adapted from the COM-B, Self-Evaluation Questionnaire
(Michie, Atkins, & West, 2015). Lack of reliability suggested that items were measuring
different facets of opportunity and capability (e.g. control over external barriers vs self-
efficacy; Ajzen, 2002). Opportunity and capability were thus represented in the analysis
by two single items, labelled according to which specific facet was assessed (opportunity:
‘If I wanted to, nothing gets in the way of me using my nebuliser’ [hereafter, ‘opportunity,
absence of obstacles’], ‘I feel I have adequate opportunity to use my nebuliser’ [‘opportu-
nity, generic’]; capability: ‘If my nebuliser is working properly, I would feel capable of
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using my nebuliser’ [‘capability, external control’], ‘I could overcome barriers to using my
nebuliser if I invest the necessary effort’ [‘capability, self-efficacy’]).
Analysis
Integration between qualitative and quantitative components
Quantitative and qualitative data were collected concurrently (Curry et al., 2013). The ‘fol-
lowing a thread’ technique was used to integrate analyses, since this technique preserves
the value of the open qualitative data whilst incorporating the focus of the quantitative
data (Moran-Ellis et al., 2006; O’Cathain, Murphy, & Nicholl, 2010). Key differences
(‘threads’) observed in the initial quantitative analysis between high and low adherers
prompted consultation of qualitative data to aid interpretation; and key insights
(‘threads’) obtained from initial qualitative analysis prompted consultation of quantitative
data.
Quantitative data analysis
This involved describing and comparing characteristics of ‘high’ and ‘low adherers’. Due
to the pragmatic but small sample size, null-hypothesis significance testing was not per-
formed. Thus, effect sizes and confidence intervals are reported, but not p-values
(Cumming, 2014). Due to a non-normal data distribution and presence of outliers,
non-parametric methods (Campbell & Gardner, 1988) were used to estimate group differ-
ences and confidence intervals for all continuous variables. This method assumes the two
groups have the same distribution shifted by a fixed parameter. The shift parameter is not
necessarily the difference in median, rather it is the median of all possible differences. For
categorical data, difference in proportions and confidence intervals were calculated using
the Wilson procedure without continuity correction (Newcombe, 1998). Linear corre-
lation between continuous variables was determined using non-parametric method
(Spearman’s rho; Altman & Gardner, 1988). All pertinent effects observed for non-specific
habit were followed up with analyses to determine whether such effects were attributable
to habitual instigation or habitual execution.
In light of a ‘thread’ that emerged from qualitative analysis, further exploratory analyses
of habit were run. In these analyses, the sample was dichotomised into those who ‘had
habit’ (high level of automaticity, habit score≥ 4, that is, at or above the scale midpoint;
see Lally, Van Jaarsveld, Potts, & Wardle, 2010) or ‘had no habit’ (habit score < 4), on each
of the three habit measures (i.e. had non-specific habit vs no non-specific habit, had insti-
gation habit vs no instigation habit, had execution habit vs no execution habit). Analyses
were run using R v3.3.0 (www.r-project.org). Graphs were generated using Prism v7
(GraphPad Software).
Qualitative data analysis
Qualitative data were thematically analysed using following Braun and Clarke’s (2006)
procedures, involving data familiarisation, generating initial codes and iteratively search-
ing for, reviewing, defining and naming themes. NVivo v10 (QSR International) was used
to organise analysis. Data were collected and analysed concurrently by the interviewer
(HZH), with two experienced qualitative researchers verifying the appropriateness of
data interpretations (JB, BG). HZH read all transcripts several times for familiarisation
and identification of patterns. JB independently analysed six (30%) transcripts to search
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for themes and verified that theoretical saturation had been reached at 17 interviews, as no
further insights emerged from subsequent analyses. A shared analytic framework was
agreed upon through discussions between the two coders. HZH then extracted pertinent
data using the agreed coding framework. At this stage, it was apparent that some of the
emergent themes tied up closely with the concepts addressed in the questionnaire, and
this helped the organisation of codes into broader themes. These themes were reviewed
and refined in discussion with BG.
Results
Quantitative results
Low adherers tended to be younger and had higher lung function (% predicted FEV1), yet
had more severe or frequent pulmonary exacerbations (i.e. greater IV antibiotics use;
median of differences 10 days [95% CIs: –4, 31]; see Table 1). Participants seemed to
have similar demographic and clinical characteristics to the local population of adults
with CF that have similar adherence levels (see Appendix Table 1).
Scores on most potential predictors were similar across both groups (see Table 2 and
Appendix Figure 1). However, low adherers had slightly lower self-regulation scores
(median of differences –0.8; [–1.4, 0.0]). There were moderate to large differences in
opportunity and non-specific habit scores between the two groups of participants, and
a strong positive correlation between those two variables (‘Opportunity, absence of
obstacles’ r = .66 [.30,.85]; ‘Opportunity, generic’ r = .75 [.46,.90]). Follow-up analyses
suggested that opportunity-habit correlations were for instigation habit (‘Opportunity,
absence of obstacles’ r = .47 [.03,.75]; ‘Opportunity, generic’ r = .51 [.09,.78]) rather than
execution habit (‘Opportunity, absence of obstacles’ r = .43 [–.01,.73]; ‘Opportunity,
generic’ r = .34 [–.11,.68]).
Low adherers reported non-specific habit scores that were on average 2.3 points lower
than high adherers [–3.5, –1.0] on a 1–7 scale. ‘Instigation habit’ may have better differ-
entiated between high adherers (median 6.5 [4.8, 7.0]) and low adherers (median 4.0 [2.8,
5.0]; median of differences 2.0 [1.0, 3.0]) than did ‘execution habit’ (high adherers median
7.0 [6.6, 7.0]; low adherers median 5.0 [4.8, 5.3]; median of differences 2.0 [1.0, 2.0]). High
adherers were more likely to ‘have non-specific habit’ (9/10 high adherers vs 3/10 low
adherers; difference in proportion = .60 [.17,.81]). High adherers (9/10) tended to be
more likely to ‘have instigation habit’ than did low adherers (6/10; difference in pro-
portion = .30 [–.08,.60]). All participants were classified as ‘having execution habit’.
Table 1. Clinical characteristics and outcomes of high (n = 10) and low (n = 10) adherers.
Low adherers,
median [IQR]
(N = 10)
High adherers,
median [IQR]
(N = 10)
Median of differences between
groups [95% CIs]
% Nebuliser adherence in
previous year
28.0 [5.3, 46.0] 94.9 [86.7, 108.5] –69.1 [–92.6, –48.9]
Age in years 21.5 [19.3, 31.3] 30.0 [18.0, 42.0] –5.3 [–13.0, 3.0]
Femalea 3 (.30) 5 (.50) .20 [–.20,.53]
Best % predicted FEV1 for the
previous year
88.0 [80.0, 96.3] 77.0 [56.0, 86.0] 13.0 [–4.0, 31.0]
IV days for the previous year 13 [0, 50] 7 [0, 16] 10 [–4, 31]
aFor gender, the proportion of female participants in each group and difference in proportion [95% CIs] were displayed.
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Qualitative results
Four themes underpinned participants’ experience of using inhaled therapy: ‘awareness &
experiences of health consequences’, ‘cues, routinisation & automaticity’, ‘prioritisation’,
and ‘coping with treatment burden’.
Awareness & experiences of health consequences
Knowledge and experience of the health benefits of using, and not using nebulised treat-
ments appeared important in motivating use among both low and high adherers.
Acute periods of ill-health reportedly made nebuliser use seemmore effortful. However,
high adherers took steps to persist with treatments in spite of difficulties (‘If I’ve got to take
it, doesn’t matter if I’m unwell or well, I’ve still got to take it in that day’; Participant 3 [P3],
high adherence), and indeed, for some, ill-health increased motivation to use nebuliser
treatment, as a means to avoid health worsening further.
Two low adherers relied exclusively on experiencing symptoms to prompt their nebu-
liser treatment, and did not use nebulisers when they felt well. Most nebulised treatments
have no immediate noticeable impact, and two low adherers reported that the relative
‘invisibility’ of health benefits made it difficult for them to appreciate the necessity of
using nebuliser.
Some preferred treatments with immediate and tangible benefits (i.e. hypertonic saline,
which typically stimulates vigorous coughing and increases sputum expectoration) over
those with less visible outcomes (dornase alfa or DNase, which more effectively improves
lung function but generally produces no immediate perceivable changes; Suri et al., 2001).
DNase I don’t know if it [makes a difference] or not, but I just believe in it. […] Hypertonic
saline definitely has a massive positive effect on my chest. So for that reason, I don’t miss
[opportunities to use my hypertonic saline]… but [this is] not [necessarily the case for]
my DNase. (P13, high adherence)
High adherers often reported experiencing beneﬁts of nebulised treatments, or had experi-
enced consequences of previous low adherence (‘I don’t get half as chesty using [my nebu-
liser regularly] now, than when I didn’t use it’; P1, high adherence).
While high adherers reported having previously been prompted by experiencing symp-
toms, for most, nebuliser motivation appeared to focus on anticipation of ill-health arising
Table 2. Psychological factors among high (n = 10) and low (n = 10) adherers.
Low adherers, median
[IQR]
(N = 10)
High adherers, median
[IQR]
(N = 10)
Median of differences between
groups [95% CIs]
Treatment complexity score 14.5 [10.0, 15.3] 15.5 [10.0, 16.5] –1.0 [–5.0, 4.0]
Perceived treatment burden 2.3 [1.4, 3.6] 1.8 [1.0, 3.5] 0.5 [–1.0, 2.0]
Self-regulation 4.6 [3.7, 4.9] 5.4 [4.5, 5.8] –0.8 [–1.4, 0.0]
Life chaos 4.5 [3.8, 5.3] 5.4 [4. 7, 5.7] –0.8 [–1.7, 0.2]
Intention 6.8 [6.4, 7.0] 7.0 [6.3, 7.0] 0.0 [–0.5, 0.5]
Capability, external control
Capability, self-efficacy
6.0 [4.0, 7.0]
6.0 [4.8, 6.0]
7.0 [7.0, 7.0]
6.5 [2.5, 7.0]
–1.0 [–3.0, 0.0]
–1.0 [–1.0, 3.0]
Opportunity, absence of
obstacles
Opportunity, generic
3.5 [2.0, 6.0]
5.0 [2.8, 6.0]
6.5 [5.8, 7.0]
6.0 [5.0, 7.0]
–3.0 [–4.0, –1.0]
–1.0 [–3.0, 0.0]
Habit
Non-specific habit
‘Instigation habit’
‘Execution habit’
3.1 [2.2, 4.0]
4.0 [2.8, 5.0]
5.0 [4.8, 5.3]
5.6 [4.4, 6.3]
6.5 [4.8, 7.0]
7.0 [6.6, 7.0]
–2.3 [–3.5, –1.0]
–2.0 [–3.0, –1.0]
–2.0 [–2.0, –1.0]
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from non-use. For example, two high adherers reported that previous highly aversive experi-
ences of severe pulmonary exacerbation due to non-adherence served as motivational remin-
ders of the importance of nebuliser use. However, experiencing or recalling symptoms did not
appear to be the predominant trigger for high adherers; rather, for most, nebuliser use had
become embedded within everyday routines and was no longer deliberately regulated.
Cues, routinisation & automaticity
Nebuliser use was commonly incorporated into existing CF-related treatment routines or
as a standalone medication activity routine within ostensibly unrelated daily activities.
First thing in a morning, I take my dogs out, come back, then the first thing I do is go to the
fridge, get my DNase out. It’s just a habit, every day. (P3, high adherence)
All high adherers described automatically ‘remembering’ to use their nebuliser. High
adherers seemed to have more durable routines and described ﬁnding treatments less bur-
densome due to routinisation (‘Once I have ﬁxed a routine that works for me… , I can
[use my treatments] all the time. I don’t have to think about it’; P12, high adherence).
Although low adherers also described automaticity to a certain extent, they tended to
describe a more ‘reflective’ process of remembering to use their nebuliser.
[Nebulised medication] is probably the only drug I have to have, where I have to think about
doing it, I have to gear myself up to using it. With my oral medications, basically I just incor-
porate that into my lifestyle. (P16, low adherence)
Some low adherers struggled to incorporate nebuliser use into their existing routines due to
irregular lifestyle, sometimes due to busy and unpredictable working patterns. In the absence
of routine, low adherers were more dependent on external reminders, such as from family
and friends, or short-lived motivational boosts from meeting health professionals.
Historical experiences of consistent nebuliser use, such as in childhood, may have con-
tributed to the development of good ‘nebuliser routines’ among high adherers.
I do my DNase in the afternoon […]. It is just how I have always done it,…when I was
younger I always did my Promixin before school and then as soon as I got home from
school about four o’clock I used to do my DNase. (P20, high adherence)
Both high and low adherers described using self-regulatory techniques, such as using
objective feedback from the nebuliser to monitor their adherence, or environmental
restructuring to support their nebuliser routines (‘I always put my I-neb near where I
sit for my breakfast in the morning as a prompt’; P10, low adherence). Similarly, both
high and low adherers reported that weekends, evenings out, holidays, or other ‘unex-
pected’ events could disrupt typical behaviour patterns, by removing contextual triggers
to nebuliser use, thus increasing the amount of conscious effort required to use the nebu-
liser. However, high adherers seemed better able to create routines less amenable to dis-
ruption, or to shield routines against disruptions, by planning preparatory behaviours
in newfound circumstances. Perhaps as a consequence of better planning, high adherers
reported that their lifestyle was more ‘supportive’ of nebuliser use.
Prioritisation
High adherers reportedly prioritised their nebulised treatments over other activities (‘say,
for example I overslept, I would do my [nebuliser] treatment but skip breakfast’; P9, high
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adherence). A high adherer reported prioritising her treatment routine when taking a new
job:
When I started the new job, [I chose my hours to fit] the routine that I have got going. I do try
and fit around other people but ultimately, I wouldn’t commit to something I couldn’t
manage whilst also doing all my treatments. (P12, high adherence)
Placing a low priority on nebuliser use was problematic for two reasons. Firstly, pursuit,
and at least temporary prioritisation, of other tasks could lead to forgetting to use nebu-
liser. Forgetting on one occasion led, for some, to longer-term derailment of adherence:
If maybe I had a couple of days off nebulisers, because I forgot it or run out, or left my nebu-
liser at home… then it just snowballs from there. (P15, low adherence)
Secondly, the completion of prioritised tasks could mentally exhaust people, so that by the
time all higher-priority tasks were completed they lacked the motivation or self-regulatory
capacity to use nebulised treatments (‘[nebuliser use] just seemed less important because
I’ve had a lot of exams at university’; P6, low adherence).
Low mood, depression and stressful life circumstances reportedly led to temporary
shifts in goal prioritisation, or depleted self-regulatory capacity to use nebulised treatment,
so potentially leading to participants ‘losing [their] routine’ (P4, low adherence).
Coping with treatment burden
Treatment was seen as burdensome by both high and low adherers, based on the number
of medications required, sequence and timing of medication, and time and effort required
to prepare and use the nebuliser and other concurrent CF treatments.
Cleaning [the nebuliser] is definitely something that gets side-lined… I just don’t do that
enough. And I think it’s because it’s about priorities and I definitely prioritise actually
doing the nebuliser over the maintenance side of it. (P12, high adherence)
Perceived treatment burden was heightened when participants were tired, stressed or other-
wise mentally depleted. However, those with high adherence appeared to cope better with
the burden. Those with signiﬁcant amounts of other CF treatments also reported struggling
to understand and resolve potentially inconsistent information from health professionals
about using their nebuliser, and balancing nebuliser with other CF treatments.
Due to perceived burden, both high and low adherers described various ‘short-cuts’ to
help them make their treatments more manageable, such as using technology or pre-
mixing nebulisedmedications to reduce treatment time, using extramedications to compen-
sate for missed doses, taking ‘treatment holidays’ to replenish self-regulatory capacity and
using distractions to deal with boredom experienced when inhaling nebulised medication.
With my promixin […] sometimes what I find myself doing is when I’ve run out, I’ll mix 30
vials up or so. […] Mixing them all up and doing them so I know they’re all here ready to go,
makes me think: right, I’ll take them. (P18, low adherence)
Several high adherers felt effective time management and planning strategies, such
as altering leisure or work routines and creating an optimal time window for nebuliser
use, minimised burden, facilitated remembering and created adequate time to complete use.
Social support from family & friends offered another way of reducing treatment
burden, with some participants receiving direct practical help with the processes involved
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in using the nebuliser, for example with cleaning the nebuliser, or indirect help to free up
time to use their nebulised treatments (‘for instance my mum comes and cleans for me
every Friday so that means that I can spend time doing my treatment […] there is lots
of other stuff that can be done to help me dedicate my time to that, and that is essential’;
P12, high adherence).
Follow-up quantitative analysis
In light of qualitative findings that routinisation reduced perceived treatment burden,
follow-up quantitative analyses were run to explore whether relationships between treat-
ment complexity and perceived burden differed according to the presence or absence of
non-specific habit and instigation habit. No such analysis was run for execution habit,
since every participant ‘had execution habit’. Participants ‘with no non-specific habit’
(n = 8) showed a moderately strong linear correlation between objective treatment com-
plexity and perceived treatment burden (r = .64 [–.12,.93]). Those ‘with non-specific
habit’ (n = 12) showed no such relationship (r = –.29 [–.74,.34]), (see Appendix
Figure 2). Similar results were obtained according to instigation habit, with a strong
linear correlation between treatment complexity and perceived burden (r = .79
[–.31,.99]) among those ‘with no instigation habit’ (n = 5), but no relationship between
the two variables (r = .04 [–.48,.54]) among those ‘with instigation habit’ (n = 15).
The consistency of findings across the two habit measures suggests that effects of non-
specific habit on burden may be more precisely attributed to habitual instigation.
Discussion
Adults with low (<50%) annual nebuliser adherence patterns were typically younger and
had better lung function (and so generally healthier), yet still required more IV antibiotics
than did ‘high adherers’ (≥80%). High adherers reported stronger habit and described
habit helping to alleviate treatment burden. Habitual instigation – that is, automatically
‘remembering’ to use nebulisers – appeared to differentiate between high and low
adherers, and reduced the impact of treatment complexity on perceived burden, such
that even complex treatment was not seen as burdensome. High adherers reported
having and seizing more opportunities to use nebuliser, and perceived opportunities cor-
related positively with habit. Due to small sample size, findings should be considered pre-
liminary, and require replication in adequately powered studies. Nonetheless, they offer
tentative evidence that adherence interventions in adults with CF might be more effective
by targeting development of routines to instigate nebuliser use, and identifying opportune
moments for nebuliser use.
All participants showed awareness of nebuliser use importance in interviews and
reported strong intentions. Adherence levels therefore do not appear attributable to differ-
ences in treatment beliefs or intention strength. There was, however, potential evidence of
different motives for nebuliser use between high adherers and low adherers. First, high
adherers with lower lung function reported they were often symptomatic when they
missed their nebuliser, whereas low adherers with higher lung function were unlikely to
notice any short-term difference when not using their nebuliser. Salient negative health
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outcomes thus appear to trigger nebuliser use. Second, some of the low adherers depended
almost exclusively on the actual experience of ill-health to prompt nebuliser use, such that
nebuliser was used only when pulmonary exacerbation has occurred. By contrast, high
adherence was more typically motivated by the anticipation of ill-health arising from
non-use, such that nebulisers were actually used to prevent exacerbation. This echoes a
literature demonstrating that anticipating regret for choosing one course of action (or
inaction) can serve as a powerful motivator for choosing alternative actions (Abraham
& Sheeran, 2003). The accrual of experiences of aversive ill-health episodes arising from
non-adherence may shift the motivation source for nebuliser use, such that people with
CF come to better understand and fear the consequences of non-adherence, which in
turn stimulates adherence. Life experience may thus represent an important determinant
of adherence. Encouraging young adults with better lung function to anticipate ill-health
arising from not using nebulised treatments, before they actually experience such ill-
health, might therefore offer a fruitful technique for them to persist with more consistent
nebuliser use.
Three key findings speak to the importance of habit formation in sustaining nebuliser
use. Firstly, high and low adherers notably differed in their habit strength, and in particu-
lar, the strength of tendencies to habitually instigate nebuliser use. All high adherers
described, in interviews, having ‘routinised’ nebuliser use, such that they automatically
‘remember’ to use their nebulisers, and reported markedly stronger tendencies to habitu-
ally instigate nebuliser use episodes than did low adherers. This supports theoretical prop-
ositions that habit formation may maintain behaviour (Rothman et al., 2009), and
empirical research suggesting habitual instigation supports frequent action (Gardner
et al., 2016; Phillips & Gardner, 2016). As habit forms, control over initially deliberative
and effortful action is delegated to environmental cues, and instigating action becomes
easier (Lally & Gardner, 2013; Lally et al., 2010). Our data suggest that some low adherers
may be stuck in the effortful early stages of habit formation, unable to develop the auto-
maticity that sustains high adherence. Indeed, younger participants – who were typically
less adherent – reported lesser habitual instigation than did older participants. Secondly,
high adherers reported that habitual instigation made treatment less burdensome. Partici-
pants ‘with instigation habit’ – that is, tending to agree that nebuliser use episodes are trig-
gered automatically, without thinking – reported low perceived treatment burden
regardless of the objective complexity of their treatment regimes. Conversely, participants
‘without instigation habit’ – that is, tending to disagree with such statement – reported
higher perceived treatment burden as treatment complexity increased. CF is a multi-
system condition requiring multiple treatment types to maintain health, so requires a
complex and potentially burdensome treatment regime (Sawicki et al., 2013). By automat-
ing the initiation of nebuliser use, instigation habit may reduce burden by bypassing delib-
eration processes (Gardner et al., 2016). Thirdly and relatedly, a moderately strong
positive correlation was also found between habitual instigation of nebuliser use and per-
ceived opportunity scores. Qualitative analysis suggested that high adherers ‘with habit’
experienced greater opportunities for nebuliser use (such as flexible working patterns),
and also adapted more effectively to generate opportunities for using nebuliser when
faced with challenges. It is not possible to determine the temporal relationship between
opportunities and habit strength due to the cross-sectional design of this study. It may
be that participants with greater opportunities were better able to form habits. Indeed,
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greater opportunity to act makes action more likely (Michie et al., 2011), thus enhancing
the likelihood of habit formation (Lally & Gardner, 2013). Alternatively, participants who
form habits may have been better placed to subsequently act on opportunities, where such
opportunities operated to automatically activate stored cue-behaviour associations. The
habit–opportunity relationships could also be bi-directional. Together, these findings
suggest that nebuliser adherence interventions might usefully focus on habit formation.
Specifically, people with CF should be encouraged to identify opportune moments in
their everyday routines, and plan to respond to such moments so that nebuliser use
might be consistently triggered, thus fostering habit associations (Lally & Gardner,
2013). Our data suggest that forming instigation habit would support adherence by not
only automating nebuliser use, but also alleviating the perceived burden of using nebuliser.
Other limitations of this study must be acknowledged. The hypothesised behaviour pre-
dictors were measured via self-report. Self-reporting habit is particularly problematic: it
has been argued that people may not reliably reflect on non-reflective processes such as
habit (Hagger, Rebar, Mullan, Lipp, & Chatzisarantis, 2015; but see Orbell & Verplanken,
2015). Participants may also have been confused by the subtly different wordings of insti-
gation and execution habit items. However, the two previous studies in this domain
suggest that people can reliably discern between the concepts of habitual instigation
and execution (Gardner et al., 2016; Phillips & Gardner, 2016). Secondly, participants’
familiarity with the interviewer (HZH) may perhaps have prompted socially desirable
responses (Neeley & Cronley, 2004). Conversely however, familiarity between the inter-
viewer and participants may have encouraged participants to speak more freely and
openly. Indeed, between-participant variation was found on predictor variables scores,
indicating that participants did not consistently self-report values to portray themselves
in a positive light. Although nebuliser use was objectively measured, only the proportion
of doses taken was considered in the calculation of ‘unadjusted’ adherence. Inadequate
prescription, brief periods of nebuliser overuse or taking nebulised antibiotics with insuf-
ficient dose spacing could inflate ‘unadjusted’ adherence (Hoo et al., 2016), and it is poss-
ible that a person with moderate levels of effective adherence was inadvertently labelled as
a high adherer in this study. Technique errors with using nebuliser were also not con-
sidered, although I-neb® is a third-generation adaptive aerosol delivery system designed
to optimised technique by only releasing aerosol when an inhalation of sufficient
quality is detected (Collins, 2009).
Previous research has focused predominantly on treatment burden and reflective
motivation concepts such as treatment beliefs. This exploratory study, which investigated
a broader range of potential adherence predictors, demonstrates the importance of both
reflective and automatic processes in determining adherence. While our findings
require replication among larger samples, they nonetheless suggest that nebuliser adher-
ence interventions for adults with CF might usefully target the development of routines to
instigate nebuliser use, identify opportune moments for using nebuliser, and utilise antici-
pated regret as a technique to support asymptomatic low adherers, especially among
younger adults with good lung function.
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